引言胰腺癌（Pancreatic cancer）是全球癌症相关死亡的第三大原因，其五年生存率低至10%，是一种预后极差的恶性肿瘤。胰腺导管腺癌（Pancreatic ductal adenocarcinoma, ...

在这一背景下，1月3日Nature Medicine的研究报道“Clinicogenomic ... 突变特异性效应：不同类型的KRAS突变（如G12D、G12V等）在剂量增益下可能具有不同的 ...

在这一背景下，1月3日Nature Medicine的研究报道“Clinicogenomic ... 突变特异性效应：不同类型的KRAS突变（如G12D、G12V等）在剂量增益下可能具有不同的 ...

Unfortunately, KRAS is largely devoid of pockets and crevices in which a therapeutic molecule can nestle, so most of its mutated forms — including the most prevalent, a variant called G12D (in ...

今日，加科思药业宣布，其自主研发的KRAS G12C抑制剂戈来雷塞（glecirasib，JAB-21822）注册性临床试验数据在《Nature Medicine》（影响因子58.7）发布 ...

Different Kirsten rat sarcoma virus (KRAS) mutations in pancreatic ductal adenocarcinoma show varying treatment responses, with G12D and G12V mutations linked to worse outcomes compared with wild ...

公司自主研发的KRAS抑制剂戈来雷塞注册性临床试验数据在医学期刊《自然医学》(Nature Medicine)发布。在文章中，加科思首次完整公开戈来雷塞治疗KRAS ...

Clinical validation of this combination has been demonstrated with the approval of adagrasib in KRASG12C-mutated CRC. Additionally, the phase 1 clinical trial evaluating QTX3034, an oral ...

Additionally, the Phase 1 clinical trial evaluating QTX3034, an oral G12D-preferring multi-KRAS inhibitor, as a monotherapy and in combination with cetuximab, continues to enroll patients ...

IND for QTX3544 is third for Quanta within one year – – Initiated combination portion of Phase 1 clinical trial of QTX3046, an oral KRAS G12D-selective dual ON/OFF state allosteric inhibitor ...